INSYS Therapeutics Inc. (INSY)

4.99
0.21 4.40
NASDAQ : Health Technology
Prev Close 4.78
Day Low/High 4.73 / 4.97
52 Wk Low/High 3.35 / 11.65
Avg Volume 752.00K
Exchange NASDAQ
Shares Outstanding 74.27M
Market Cap 355.01M
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed In U.S. District Court To Recover Losses Suffered By Investors In INSYS Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of INSYS Therapeutics, Inc.

May 16 Deadline Alert: Law Offices Of Howard G. Smith Reminds Insys Therapeutics, Inc. Investors Of Upcoming Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith reminds investors of the upcoming  May 16, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise...

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

These heavily shorted stocks could squeeze the short-sellers if they report bullish earnings this week.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed In U.S. District Court To Recover Losses Suffered By Investors In INSYS Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of INSYS Therapeutics, Inc.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biotech Movers Trading Positive Ahead of Market's Open

Biotech Movers Trading Positive Ahead of Market's Open

Intellia Therapeutics led the movers.

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Insys Therapeutics, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Insys Therapeutics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In INSYS Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

Senator McCaskill Launching Investigation Into Opioid Drugmakers

Senator McCaskill Launching Investigation Into Opioid Drugmakers

The U.S. Centers for Disease Control and Prevention says 91 Americans die every day as a result of an overdose.

INSY NOTICE: Rosen Law Firm Reminds Insys Therapeutics, Inc. Investors Of Important Deadline Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Insys Therapeutics, Inc.

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

First Week of INSY November 17th Options Trading

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Insys Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Insys Therapeutics, And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc.

Insys Falls on Earnings Delay

Insys Falls on Earnings Delay

Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.

Insys Therapeutics Announces Delay In The Release Of Its Fourth Quarter And Full Year 2016 Results

-- Fourth Quarter 2016 Net Sales Estimated at $54 million --

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Short Interest Drops 14.7% For INSY

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc , to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D (Sell)